文献速递头痛与眩晕

阿托吉泮与托吡酯治疗成人偏头痛的头对头3b期试验

Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.
PubMed 文献 · Lancet Neurol · 2026-07-23

TEMPLE试验为3b期随机双盲活性对照研究,在12国纳入545例成人偏头痛患者,比较阿托吉泮60mg每日一次与托吡酯(最高耐受剂量50/75/100mg/日)的耐受性、安全性和疗效。

要点

  • 阿托吉泮因不良事件停药率显著低于托吡酯(12% vs 30%)
  • 阿托吉泮月偏头痛天数减少≥50%比例更高(64% vs 39%)

核心结论

  • 阿托吉泮60mg每日一次在24周内耐受性和疗效均优于托吡酯。

研究设计与样本

  • TEMPLE为3b期随机双盲双模拟活性对照试验,含24周双盲期和52周开放标签期,在12个国家开展。
  • 筛选730例,随机545例,安全性人群540例(阿托吉泮273例,托吡酯267例;女性479例[89%],男性61例[11%];白人517例[96%])。

主要发现

  • 治疗相关不良事件:阿托吉泮组153/273例(56%),托吡酯组208/267例(78%)。
  • 严重治疗期不良事件:阿托吉泮组6例,托吡酯组3例;1例严重不良事件(阿托吉泮组过敏反应)被认为与研究药物相关;无死亡。

临床怎么用

  • 对于偏头痛预防治疗,阿托吉泮60mg每日一次较托吡酯具有更好的耐受性和疗效,可指导临床选择。

局限性

  • 开放标签期仍在进行中,双盲期结果仅覆盖24周。
  • 研究人群以女性和白人为主(女性89%,白人96%),外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral calcitonin gene-related peptide (CGRP) receptor antagonists such as atogepant have been approved for preventive treatment of migraine but have not been compared directly with conventional oral non-specific preventive treatments. Topiramate is a widely used conventional oral non-migraine-specific preventive treatment for migraine but its use is often limited by poor tolerability. We aimed to evaluate the tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine, to provide direct comparative evidence to help inform treatment selection. METHODS: TEMPLE was a phase 3b, randomised, double-dummy, active-controlled trial with a 24-week double-blind treatment period and a 52-week open-label treatment period, done in sites with experience in diagnosing and treating migraine across 12 countries (Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Portugal, and the UK). Participants had a history of migraine and at least 4 migraine days per month on average across the 3 months before screening and during the combined screening and baseline period. Participants were randomly assigned 1:1 to atogepant (60 mg once daily) or topiramate (highest tolerated dose of 50 mg/day, 75 mg/day, or 100 mg/day) using interactive response technology. The primary endpoint assessed tolerability by measuring treatment discontinuation owing to treatment-emergent adverse events during the double-blind period in the safety population (all participants who received ≥1 dose of the study treatment during the double-blind period). Secondary efficacy endpoints related to clinical efficacy were at least 50% reduction from baseline in mean monthly migraine days and change from baseline in mean monthly migraine days during months 4-6 in the modified intention-to-treat population (all randomised participants who received ≥1 dose of study treatment, had an evaluable baseline period of eDiary data, and had ≥1 evaluable postbaseline 4-week [1 month] period of eDiary data within 24 weeks after first dose of study medication [month 1 to month 6], regardless of whether on study treatment or off study treatment). TEMPLE is registered with ClinicalTrials.gov (NCT05748483) and EU Clinical Trials Register (2022-501172-25-00); the double-blind period is completed and the open-label period is ongoing. FINDINGS: Between Oct 7, 2023, and April 28, 2025, 730 participants were screened, 545 were randomly assigned, and 540 (479 [89%] female and 61 [11%] male, 517 [96%] White) were included in the safety population (atogepant n=273; topiramate n=267). Discontinuation due to treatment-emergent adverse events across the 24-week double-blind period was lower in the atogepant group (33 [12%] of 273) compared with the topiramate group (79 [30%] of 267; relative risk [RR] 0·4, 95% CI 0·3 to 0·6; p<0·0001). Treatment-related adverse events were reported by 153 (56%) of 273 participants in the atogepant group and 208 (78%) of 267 in the topiramate group. Serious treatment-emergent adverse events occurred in six participants on atogepant and in three participants on topiramate. One serious treatment-emergent adverse event (anaphylactic reaction in the atogepant group) was considered related to study drug. No deaths occurred. More participants experienced at least 50% reduction in mean monthly migraine days in the atogepant group (64% [173 of 270]) compared with the topiramate group (39% [101 of 257], RR 1·6, 95% CI 1·4 to 2·0, p<0·0001) and reduction from baseline in mean monthly migraine days was greater in the atogepant group (least squares mean -6·3 [SE 0·3]) than the topiramate group (-4·5 [0·3]; treatment difference -1·8 [-2·5 to -1·0]; p<0·0001). INTERPRETATION: Atogepant 60 mg once daily showed better tolerability and efficacy across 24 weeks compared with topiramate. Although both topiramate and atogepant are established as effective oral migraine preventive treatments, their usefulness in clinical practice hinges on patients' ability to tolerate treatment. Our findings provide direct comparative evidence that might guide clinicians in selecting the most appropriate preventive therapy for their patients. FUNDING: AbbVie.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Reuter U, Dycke AV, Versijpt J, et al. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. Lancet Neurol. 2026. PMID: 42492556. doi:10.1016/S1474-4422(26)00214-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。